Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.49 |
| ▸ | JAK2 | O60674 | 6/20 | 0.46 |
| ▸ | JAK3 | P52333 | 6/20 | 0.46 |
| ▸ | JAK1 | P23458 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269155 | 0.85 | CHIT1 (0.42) | CHRM4PANK3 | |
| SCHEMBL3265671 | 0.85 | DEGS1 (0.49) | AOC3GPR119 | |
| SCHEMBL3266209 | 0.85 | CKS1B (0.44) | PANK3AOC3GPR119 | |
| SCHEMBL1729285 | 0.83 | CHRM4 (0.57) | CHRM4JAK2JAK3JAK1KCNH2 | |
| SCHEMBL3266247 | 0.83 | HRH3 (0.46) | AOC3 | |
| SCHEMBL3265642 | 0.82 | CKS1B (0.51) | — | |
| SCHEMBL3265636 | 0.82 | KDM4E (0.58) | CHRM4CHRM2CHRM1 | |
| SCHEMBL3269094 | 0.81 | CKS1B (0.47) | CHRM4KCNH2 | |
| SCHEMBL30549291 | 0.81 | PANK3 (0.53) | CHRM4JAK2JAK3JAK1KCNH2 | |
| SCHEMBL2225824 | 0.81 | PANK3 (0.53) | CHRM4JAK2JAK3JAK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CHRM4 243/4885JAK2 2520/4885JAK3 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.